Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 1:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 86 matching trials from the live ClinicalTrials.gov search.
Conditions
Liver and Intrahepatic Bile Duct Carcinoma
Interventions
Computed Tomography Perfusion Imaging, Liver Biopsy
Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Houston, Texas
Conditions
Coronary Artery Disease, Chest Pain, Coronary Atherosclerosis, Stress Testing
Interventions
Cardiac CT Angiography, Stress Imaging Test (Stress Myocardial Perfusion Study or Stress Echocardiogram)
Procedure
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Coronary Artery Disease (CAD)
Interventions
regadenoson, technetium Tc99m sestamibi /technetium Tc99m tetrafosmin, Contrast, Single Photon Emission Computed Tomography, Multidetector Computed Tomography
Drug · Radiation · Procedure
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
45 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Roseville, California • Torrance, California • Miami, Florida + 6 more
Conditions
Ischemic Stroke
Interventions
Computed tomography perfusion imaging
Other
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
San Francisco, California
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Computed Tomography Perfusion Imaging
Radiation
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Coronary Artery Disease
Interventions
Cardiac Perfusion Rest/Stress Digital PET/CT, N-13 ammonia, Regadenoson
Diagnostic Test · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Stanford, California
Conditions
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Interventions
Scintigraphy scan
Diagnostic Test
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
New York, New York • Durham, North Carolina • Cleveland, Ohio + 1 more
Conditions
MRI Scans
Interventions
Adenosine, Regadenoson, O-15 labeled radioactive water, MRI, PET Imaging
Drug · Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Coronary Artery Disease
Interventions
Antigravity treadmill (Alter-G), Conventional treadmill/regadenoson
Device
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Coronary Artery Disease, Coronary Artery Bypass Graft (CABG)
Interventions
Hyperpolarized 13C Pyruvate Magnetic Resonance Imaging (HP-13C MRI), [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), SPECT MPI (Single Photon Emission Computed Tomography Myocardial Perfusion Imaging)
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
20 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Completed Not applicable Interventional Results available

Myocardial Stress Perfusion Imaging With Dual Source CT

NCT00853671
Conditions
Coronary Artery Disease
Interventions
Adenosine Stress Dual-source CTP
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Chest Pain
Interventions
SPECT Imaging Test at Baptist hospital, CT Angiography and CT myocardial perfusion at West Kendall Baptist Hospital, SPECT Imaging Test at West Kendall Baptist Hospital
Diagnostic Test
Lead sponsor
Baptist Health South Florida
Other
Eligibility
35 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Miami, Florida
Conditions
Coronary Artery Disease, Ischemia
Interventions
Computed Tomography Angiography
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Chest Pain, Stable Angina Pectoris, CCS Class I to III, Angina Equivalent, Coronary Artery Disease
Interventions
CCTA, SPECT MPI/ICA
Device
Lead sponsor
American College of Radiology
Other
Eligibility
40 Years and older
Enrollment
1,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Decatur, Georgia • Detroit, Michigan • Salem, Virginia
Conditions
Myocardial Ischemia, Coronary Artery Disease, Myocardial Infarction
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
20 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
2
States / cities
Bethesda, Maryland
Conditions
Coronary Artery Disease
Interventions
Apadenoson SPECT-MPI, Adenosine SPECT-MPI
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
863 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
103
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 87 more
Completed Early Phase 1 Interventional Accepts healthy volunteers

Image and Model Based Analysis of Lung Disease

NCT03764163
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Pulmonary Function Test, CT Scans, Questionnaires, MRI, Xenon gas
Diagnostic Test · Behavioral · Biological
Lead sponsor
Eric A. Hoffman
Other
Eligibility
20 Years to 89 Years
Enrollment
341 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2015
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Coronary Artery Disease
Interventions
Rest/Dipyridamole Stress Rb-82 Myocardial Perfusion PET/CT, Rest/Lexiscan(TM) Stress Rb-82 Myocardial Perfusion PET
Drug
Lead sponsor
Cardiovascular Imaging Technologies
Industry
Eligibility
35 Years to 90 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Kansas City, Missouri
Conditions
Myocardial Perfusion Imaging, Myocardial Ischemia
Interventions
Ranolazine, Placebo to match ranolazine, SPECT MPI, Exercise
Drug · Procedure · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
26
States / cities
Birmingham, Alabama • Imperial, California • Lincoln, California + 23 more
Conditions
Coronary Artery Disease
Interventions
Apadenoson SPECT-MPI, Adenosine SPECT-MPI
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
45
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 37 more
Conditions
Coronary Artery Disease, Myocardial Ischemia, Heart Disease
Interventions
SPECT imaging, PET imaging
Other
Lead sponsor
Hartford Hospital
Other
Eligibility
50 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
5
States / cities
Huntsville, Alabama • Hartford, Connecticut • Kansas City, Missouri + 2 more
Conditions
Polycystic Kidney Disease, Adult, Polycystic Kidney, Autosomal Dominant
Interventions
Aminohippurate Sodium Inj 20%, Iohexol Inj 300 milligrams per milliliter (MG/ML), PET/CT Scan
Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinofibroma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions
Bevacizumab, Carboplatin, Computed Tomography, Paclitaxel, Therapeutic Conventional Surgery
Biological · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
559
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 374 more